Treatment of Refractory and Relapsed Acute Leukemias with Cytosine Arabinoside and Mitoxantrone
In the last few years several new agents for the treatment of acute leukemia have been studied. These have included amsacrine, idarubicin, mitoxantrone, homoharringtonine and most recently diaziquone . Mitoxantrone is a relatively new synthetic anthracenedione derivative with strong antineoplastic activity in vitro and in vivo against solid tumors and leukemias .
KeywordsAcute Leukemia Partial Remission Acute Myelogenous Leukemia Complete Remission Rate Cytosine Arabinoside
Unable to display preview. Download preview PDF.
- 3.Rozmyslowicz T, Palynyczko G, Mazur J, Konopka L (1991) Mitoxantrone in the treatment of malignant haematological disorders (in Polish). Terapia i Leki 10: 255–262Google Scholar
- 11.Rozmyslowicz T, Palynyczko G, Mazur J et al. (1990) Mitoxantrone in treatment of refractory acute leukemias. Blood 76 (10) [Suppl 1]: 315aGoogle Scholar
- 12.Arlin ZA, Case D, Moore J et al. (1988) Randomized trial of mitoxantrone and daunorubicin-based therapy in untreated acute myelogenous leukemia. Am Soc Clin Oncol 7: 186Google Scholar